Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.48 |
| ▸ | CTSL | P07711 | 11/20 | 0.48 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11889785 | 0.79 | CTSB (0.62) | CTSSCTSLCTSBCTSCCTSK | |
| SCHEMBL3873085 | 0.79 | CTSS (0.51) | CTSSCTSLCTSBCTSK | |
| SCHEMBL5456972 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSCCTSK | |
| SCHEMBL16626138 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSCCTSK | |
| SCHEMBL5924660 | 0.79 | CTSS (0.67) | CTSSCTSLCTSBCTSCCTSK | |
| SCHEMBL11889719 | 0.78 | CTSC (0.44) | CTSSCTSLCTSBCTSCCTSK | |
| SCHEMBL4398295 | 0.78 | ALPI (0.55) | — | |
| SCHEMBL4398300 | 0.78 | ALPI (0.55) | — | |
| SCHEMBL5405898 | 0.78 | CTSL (0.49) | CTSSCTSLCTSBCTSCCTSK | |
| SCHEMBL3869381 | 0.78 | CTSC (0.67) | CTSSCTSLCTSBCTSCCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | CTSS 2/4885CTSL 8/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.